Person: URSAVAŞ, AHMET
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
URSAVAŞ
First Name
AHMET
Name
52 results
Search Results
Now showing 1 - 10 of 52
Publication Efficacy of nasal surgery on snoring(Galenos Yayıncılık, 2010-09-01) Sufiolu, M.; Özmen, Ömer Afşin; Kasapoğlu, Fikret; Ursavaş, Ahmet; Erisen, L.; Onart, S.; Sufiolu, M.; ÖZMEN, ÖMER AFŞIN; KASAPOĞLU, FİKRET; URSAVAŞ, AHMET; Erisen, L.; Onart, S.; Tıp Fakültesi; Kulak Burun Boğaz Ana Bilim Dalı; 0000-0002-9698-0546; A-1452-2019; AAI-3877-2021; AAI-3169-2021; GCI-1390-2022; ETY-7294-2022; FQP-9099-2022Objectives: The aim of the study was to investigate the effect of corrective nasal surgeries on snoring in patients diagnosed as simple snorers.Methods: Seventeen patients who were presented with the complaint of snoring as suggested by their partners and had apnea hypopnea index less than 5 in polysomnography, and were operated on due to nasal pathology were included in the study. Patients were evaluated prior to surgery and 3 months after surgery with body mass index, snoring complaints inventory and visual analog scala (VAS) for symptoms of snoring and apnea, nasal obstruction and post-operative satisfaction.Results: In the post-operative assessment, significant improvement was observed in the nasal passage compared to pre-operative level. This finding was approved subjectively on survey study as increase of nasal passage in 71% of the patients. Decrease in snoring was found in 65% of the patients. VAS scores revealed a significant reduction in the loudness of the snoring in the post-operative period.Conclusion: Correction of the nasal pathology leads to reduction in the frequency and loudness of the snoring. Consequently, nasal pathologies should definitely be treated in patients with snoring. However, it should be borne in mind that these diseases are multifactorial and multi-leveled. Thus, successful results may not be obtained in all of the patients and they should be counseled accordingly.Publication The relationship between serum periostin levels, 6-minute walking test and quality of life in patients with idiopathic pulmonary fibrosis(Carbone Editore, 2019-01-01) Eken, Özge Aslantekin; ASLANTEKİN EKEN, ÖZGE; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Demirdöğen, Ezgi; DEMİRDÖĞEN, EZGİ; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Ursavaş, Ahmet; URSAVAŞ, AHMET; Budak, Ferah; BUDAK, FERAH; Karadağ, Mehmet; KARADAĞ, MEHMET; Tıp Fakültesi; İmmunoloji Ana Bilim Dalı; 0000-0003-3604-8826; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0001-7625-9148; 0000-0002-9027-1132; AAG-8744-2021; AAI-3169-2021; JPK-7012-2023; AAD-1271-2019; IZP-9398-2023; F-4657-2014; AAH-9812-2021Introduction: Interstitial lung disease (ILD) is a group of chronic respiratory diseases characterized by inflammation and fi-brosis in different patterns at the interstitium, which is the most common form of idiopathic pulmonary fibrosis (IPF). Considering the prevalence, incidence, and outcomes of IPF, it is important to ensure the availability and validity of biomarkers that can be used in determining the diagnosis and prognosis. In this study, we aimed to assess the relationship between serum periostin levels, pulmonary function tests, 6-minute walking test (6MWT) and quality of life in IPF patients.Material and methods: Our study was carried out with 40 IPF patients who were followed at Uludag University, Faculty of Medicine, Department of Pulmonary Medicine. Spirometer and carbon monoxide diffusion test (DLCO) for respiratory functions, 6MWT and periostin level measurement were performed on the patients, and results were recorded.Results: A total of 31 of patients were males and nine were females. The diagnosis of IPF was made according to the guidelines of ATS / ERS / JRS / ALAT with 25 (62.5%) patients by radiologically and 15 (37.5%) patients with histopathological and radiological features. The mean periostin level was 32.9 +/- 37.57 ng/ml. No significant correlation was found between St. George's Respiratory Questionnaire (SGRQ) score, FVC% predicted, DLCO adj% predicted values, 6MWT distance and periostin level which were measured simultaneously. A negative correlation was found between SGRQ score and DLCO adj% predicted value, 6MWT distance.Conclusion: It has been shown that there is no correlation between periostin levels and the results of the pulmonary function tests, when measured and performed at the same time. No studies are evaluating the relationship between 6MWT and SGRQ scores and periostin levels. In our study, serum periostin level, pulmonary function test results, 6MWT and SGRQ scores were not significantly correlated.Publication Frailty: An indicator for poor outcomes among in-hospital pulmonology patients(European Respiratory Soc Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Dilektaşlı, Aslı Görek; Güçlü, Özge Aydın; Ursavaş, Ahmet; Demirdoğen, Ezgi; Coşkun, Funda; Uzaslan, Esra; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; JPK-7012-2023; AAG-8744-2021; AAD-1271-2019; Z-1424-2019; CNP-1063-2022; AAG-9930-2019; CDI-1977-2022Publication Effects of coronavirus disease 2019 (covid-19) pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: A cross-sectional multicenter study phone call survey(European Respiratory Soc Journals, 2021-09-05) Hanta, Ismail; Cilli, Aykut; Ozkaya, Guven; ÖZKAYA, GÜVEN; Coskun, N. Funda; Ursavas, Ahmet; URSAVAŞ, AHMET; Sevinc, Can; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0003-3604-8826; 0000-0002-4069-9181; AAI-3169-2021Publication Impact of covid-19 pneumonia on pulmonary function, functional exercise capacity and quality of life(European Respiratory Soc Journals, 2021-09-05) Dilektasli, Asli Gorek; GÖREK DİLEKTAŞLI, ASLI; Ozturk, Nilufer; ACET ÖZTÜRK, NİLÜFER AYLİN; Odabas, Ayten; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Ursavas, Ahmet; URSAVAŞ, AHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Guclu, Ozge Aydin; AYDIN GÜÇLÜ, ÖZGE; Ediger, Dane; EDİGER, DANE; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Tıp Fakültesi; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0003-1005-3205; 0000-0002-2954-4293; AAI-3169-2021; AAE-9142-2019; JPK-7012-2023; AAD-1271-2019Publication Evaluation of fibrinogen levels in patients with obstructive sleep apnea syndrome(Wiley, 2013-11-01) Çetinoğlu, Ezgi Demirdoğen; Ursavaş, Ahmet; Karadağ, Mehmet; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Ege, Ercüment; Gözü, Oktay; Çetinoğlu, Ezgi Demirdoğen; URSAVAŞ, AHMET; KARADAĞ, MEHMET; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; Ege, Ercüment; Gözü, Oktay; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-7400-9089; 0000-0002-9027-1132; 0000-0003-3604-8826; 0000-0002-2954-4293; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; AAE-9142-2019; AAH-9812-2021; CDI-1977-2022; CPF-5844-2022; JLC-5863-2023Publication Comparison of clinical, laboratory, and radiological characteristics between COVID-19, influenza, and adenovirus pneumonia: A narrative review(Galenos Yayıncılık, 2021-01-01) Önal, Uğur; Ursavaş, Ahmet; Akalın, Halis; ÖNAL, UĞUR; URSAVAŞ, AHMET; AKALIN, EMİN HALİS; Tıp Fakültesi; Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı; 0000-0001-6194-3254; 0000-0001-7530-1279; 0000-0001-6953-8499; ACQ-7832-2022; AAI-3169-2021; AAU-8952-2020; JCO-3678-2023The Coronavirus disease-2019 (COVID-2019) pandemic is a major global healthcare problem nowadays, and because of the high numbers of infected patients, it is vitally important to distinguish this from other types of viral pneumonia caused by influenza or adenovirus, which may have similar signs and symptoms. We conducted a narrative literature review and performed a PubMed and Scopus search for studies published up to November 18, 2020, using the following medical subject headings terms: ["comparison," "comparisons" AND "severe acute respiratory syndrome coronavirus 2," "ncov," "2019 ncov," "covid 19," "sars coy 2," "coronavirus," "coy" AND ("influenzas," "influenza," "influenzae," "human influenza" OR "adenoviridae," "adenovirus," "adenoviridae infections")]. This narrative review aims to compare pneumonia caused by severe acute respiratory syndrome coronavirus-2, influenza, and adenovirus in terms of clinical, laboratory, and radiological characteristics. In conclusion, although these viral pneumonia clinics share the similar patterns of symptoms and laboratory findings; we believe that there have some distrinctions especially in radiological findings.Publication Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Cilli, Aykut; Hanta, Ismail; Sevinc, Can; Odemi, Ayse; Coskun, Necmiye Funda; COŞKUN, NECMİYE FUNDA; Ursavas, Ahmet; URSAVAŞ, AHMET; Tıp Fakültesi; 0000-0003-3604-8826; 0000-0002-4069-9181; AAI-3169-2021; AAD-1271-2019Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting. Materials and methods: A retrospective, multicenter study conducted in four university hospitals in Turkey between January 2017 and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total 2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage, where appropriate. Results: The study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated with the treatment was observed in 28 (37.3%) patients. Conclusion: Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patients.Publication AVAPS-NIV treatment in hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV(Türk Tüberküloz ve Toraks, 2022-01-01) Öztürk, Nilüfer Aylın Acet; Güçlü, Özge Aydın; Demirdöğen, Ezgi; Dilektaşlı, Asli Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; DDT-7334-2022Introduction: Noninvasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF) is an established treatment modality. Current evidence does not conclude any superiority between fixed pressure support (PS) and aver-age volume-assured pressure support (AVAPS) modes. However, given the ability of rapid PaCO2 decline in AVAPS mode, we hypothesized that COPD patients with AHRF who did not show the desired reduction in PaCO2 with fixed-level PS-NIV might benefit from the AVAPS mode.Materials and Methods: Patients admitted to the non-ICU pulmonary ward with acute exacerbation of COPD (AECOPD) and AHRF were included con-secutively in this observational study. Patients with hypercapnic respiratory failure due to obesity-hypoventilation, neurological diseases, or chest wall deformities were excluded. All patients started NIV treatment with fixed pres-sure support (PS) and patients who did not reach clinical and laboratory stability under PS-NIV treatment were switched to the average volume -as-sured pressure support (AVAPS) mode of NIV.Results: Thirty-five COPD patients with hypercapnic respiratory failure were included. Under PS-NIV treatment, 14 (40%) patients showed a 17.9 (-0.0-29.2) percent change in terms of PaCO2 , meaning no improvement or worsening. Therefore, these patients were treated with AVAPS mode. Arterial PaCO2 and pH levels significantly improved after AVAPS-NIV administration. AVAPS-NIV treatment created a significantly better PaCO2 change rate than using PS-NIV (-11.4 (-22.0 --0.5)vs 8.2 (-5.3-19.5), p= 0.02]. Independent predictors of AVAPS mode requirement were higher Charlson Comorbidity Index (OR= 1.74 (95% CI= 1.02-2.97)] and higher PaCO2 upon admission (OR= 1.18 (95% CI= 1.03-1.35)]. Thirteen (92.8%) patients reaching signif-icant clinical stability with AVAPS-NIV were able to return to fixed-level PS-NIV and maintain acceptable PaCO2 levels.Conclusion: Our study demonstrated that patients can benefit from AVAPS-NIV despite insufficient response to fixed-level PS-NIV.Publication Serum cancer from lung-6: Promising biomarker to differentiate cpfe from ipf(Mattioli 1885, 2022-01-01) Uzaslan, Esra; DEMİRDÖĞEN, EZGİ; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; ÖZKAYA, GÜVEN; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer Aylin Acet; Karadağ, Mehmet; KARADAĞ, MEHMET; ACET ÖZTÜRK, NİLÜFER AYLİN; YEŞİLBURSA, DİLEK; Yeşilbursa, Dilek; Budak, Ferah; BUDAK, FERAH; Öztürk, Alper; Ursavaş, Ahmet; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-6375-1472; 0000-0001-7625-9148; 0000-0003-3604-8826; 0000-0003-0297-846X; 0000-0002-9027-1132; AAD-1271-2019; JPK-7012-2023; IZP-9398-2023; A-4421-2016; F-4657-2014; AAI-3169-2021; AAG-8744-2021Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.